ライフサイエンスコーパス: corticosteroid

1 respond to traditional asthma therapies (ie, corticosteroids).

2 l to 10% improvement in FEV1 with parenteral corticosteroid.

3 inistration, with or without the addition of corticosteroids.

4 relief of symptoms, and daily use of inhaled corticosteroids.

5 ult stable asthmatic patients taking inhaled corticosteroids.

6 ular events (8%) may benefit from short-term corticosteroids.

7 cerbations requiring treatment with systemic corticosteroids.

8 ith severe disease and requiring intravenous corticosteroids.

9 ong those initially treated with intravenous corticosteroids.

10 ed mandatory taper to discontinue their oral corticosteroids.

11 of severe exacerbations and the dose of oral corticosteroids.

12 and PCR sequencing in UC patients receiving corticosteroids.

13 ciated with increased sST2 in UC patients on corticosteroids.

14 er day at week 49; 5 responders discontinued corticosteroids.

15 At baseline, 56 eyes (75%) were on topical corticosteroids.

16 who differed in molecular responses to oral corticosteroids.

17 icosteroids, and 315 to placebo plus topical corticosteroids.

18 applied; FBS, IUPT, or IVIG with or without corticosteroids.

19 -13 (MCP-4) in both asthma groups after oral corticosteroids.

20 y differential adherence or incorrect use of corticosteroids.

21 er morbidity and reduced response to inhaled corticosteroids.

22 anti-IgE, 10.7% theophylline, and 16.0% oral corticosteroids.

23 cells recovered after treatment with inhaled corticosteroids.

24 rin inhibitors where inadvisable for topical corticosteroids.

25 corticosteroids, but responsive to systemic corticosteroids.

26 n patients treated with placebo plus topical corticosteroids.

27 , which appears to be further exaggerated by corticosteroids.

28 al corticosteroids, and 143 with intravenous corticosteroids.

29 does not influence the response to systemic corticosteroids.

30 terize IgAN indicate a potential benefit for corticosteroids.

31 ly explain their reduced response to inhaled corticosteroids.

32 se associated with keratitis include topical corticosteroids.

33 1, and response to both inhaled and systemic corticosteroids.

34 advantages over starting treatment with oral corticosteroids.

35 2.7%, and 34.2% received local injections of corticosteroids.

36 nolate mofetil and 1 bolus of intraoperative corticosteroids (0-1000 mg) as per center policy.

37 ndomly assigned to dupilumab qw plus topical corticosteroids, 106 to dupilumab q2w plus topical corti

38 4], theophylline: 2.46 [1.23-4.91], and oral corticosteroids: [2.99;.1.26-7.08]).

39 l prescriptions for self-administration: 67% corticosteroids, 83% antihistamines, and 9% intramuscula

40 ients who received dupilumab qw plus topical corticosteroids, 97 (88%) patients who received dupiluma

41 patients who received dupilumab plus topical corticosteroids achieved the coprimary endpoints of IGA

42 orticosteroids supports the prolonged use of corticosteroids after DMEK.

43 To determine whether corticosteroid alone or in combination with a LABA alter

44 s, is effective in patients for whom inhaled corticosteroids alone are insufficient.

45 of asthma, but the effects of treatment with corticosteroids alone or in combination with a long-acti

46 duced the rate of exacerbations treated with corticosteroids alone or with corticosteroids and antibi

47 acerbation requiring treatment with systemic corticosteroids among all participants (adjusted inciden

48 y recommend the combination of an intranasal corticosteroid and an intranasal antihistamine for initi

49 Corticosteroid and antifungal therapy perturb this respo

50 him with intramuscular adrenaline injection, corticosteroid and antihistamine infusions, volume resus

51 rove under the initial treatment of systemic corticosteroid and calcium channel blocker, remarkable i

52 es included potential systemic toxicities of corticosteroid and immunosuppressive therapy and death.

53 MA), licensed as triple therapy with inhaled corticosteroid and long-acting beta-agonist (ICS/LABA).

54 analysed 214 patients (114 extrafine inhaled corticosteroids and 100 placebo).

55 s treated with corticosteroids alone or with corticosteroids and antibiotics but not the rates of tho

56 s were minor and responded to treatment with corticosteroids and antihistamines.

57 urther study to test the efficacy of inhaled corticosteroids and beta agonists for prevention of acut

58 Early treatment with inhaled corticosteroids and beta agonists may reduce progression

59 Three eyes received intravitreal corticosteroids and had final visual acuities of 20/40,

60 Thus, oral corticosteroids and immunosuppression may be a preferred

61 s trial comparing systemic therapy with oral corticosteroids and immunosuppression with regional cort

62 eitides requiring treatment are treated with corticosteroids and immunosuppression.

63 ssess and compare the efficacy and safety of corticosteroids and interferon-alpha (IFN-alpha) in adul

64 her exploration into the mechanisms by which corticosteroids and long-acting beta2 -adrenergic agonis

65 Inhaled corticosteroids and long-acting beta2-agonist combinatio

66 Combination therapy, including inhaled corticosteroids and long-acting beta2-agonists, is effec

67 S) I showed a significant benefit of topical corticosteroids and oral acyclovir for stromal keratitis

68 dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, systemic i

69 different susceptibilities to the actions of corticosteroids and, in some, corticosteroids enhance th

70 in respiratory health requiring therapy with corticosteroids and/or antibiotics, and severe exacerbat

71 who initiated with mesalazine, 141 with oral corticosteroids, and 143 with intravenous corticosteroid

72 osteroids, 106 to dupilumab q2w plus topical corticosteroids, and 315 to placebo plus topical cortico

73 lazine, 50.4 (13.8) in those initiating oral corticosteroids, and 66.9 (13.7) in those initiating int

74 c pathways, delineating their sensitivity to corticosteroids, and determining the balance between reg

75 ncy of administration of H1 and H2 blockers, corticosteroids, and epinephrine was similar in the 2 tr

76 -inflammatory medications (statins, aspirin, corticosteroids, and nonsteroidal anti-inflammatory drug

77 ministration-to-birth intervals of antenatal corticosteroids (ANS) vary.

78 agement of ME associated with BRVO; however, corticosteroids are associated with increased potential

79 I evidence also indicates that intravitreal corticosteroids are effective and safe for the managemen

80 Topical nasal corticosteroids are the treatment of choice for moderate

81 cocorticoids (GCs; referred to clinically as corticosteroids) are steroid hormones with potent anti-i

82 ith increased risk of treatment with inhaled corticosteroids at age 7 years (adjusted odds ratio, 4.0

83 hmatics that were being treated with inhaled corticosteroids at the time of the study.

84 od responders and poor responders to inhaled corticosteroids based on a subset of 145 white children

85 hemotherapy-naive LSCC patients treated with corticosteroids before surgery, compared with untreated

86 n Accelerated intravenous premedication with corticosteroids beginning 5 hours before contrast-enhanc

87 ncreased with severity in those treated with corticosteroids but were also elevated in untreated, mil

88 nflammation that was unresponsive to inhaled corticosteroids, but responsive to systemic corticostero

89 nce was observed in visual outcome with oral corticosteroids, but subjects treated with anti-VEGF had

90 ecutive patients with severe AH treated with corticosteroids, collected from March 2010 through Febru

91 ; 38 774 filled prescriptions for antibiotic-corticosteroid combination products.

92 either their monocomponents or LABA/inhaled corticosteroid combinations in patients at low and high

93 ND Inhaled corticosteroids (ICS) and inhaled corticosteroids combined with long-acting beta2-agonist

94 was 35% among patients who had received oral corticosteroids compared with 42% among those who had no

95 ssociated with the physiological response to corticosteroids, confirming the importance of measuring

96 ith active cGVHD with inadequate response to corticosteroid-containing therapies.

97 Topical corticosteroids could be tapered, stopped, or restarted

98 Intra-articular corticosteroids could reduce cartilage damage associated

99 lial barrier or, alternatively, is linked to corticosteroid (CS) therapy.

100 the efficacy of the addition of rituximab to corticosteroids (CSs) and cyclosporine A (CsA) as first-

101 n of topical and systemic therapies, such as corticosteroids, dapsone, isotretinoin, and/or antibioti

102 miniAQLQ scores after ESS were pre-operative corticosteroid dependency (P = 0.011) and change in tota

103 tioning and quality of life in patients with corticosteroid-dependent noninfectious intermediate uvei

104 n from latency is initiated by the synthetic corticosteroid dexamethasone.

105 This study examines the association between corticosteroid dosage and incidence rates of corticoster

106 Median corticosteroid dose in responders decreased from 0.29 mg

107 was estimated controlling for time-dependent corticosteroid dose, age, sex, prior oral corticosteroid

108 nt corticosteroid dose, age, sex, prior oral corticosteroid dose, prior topical corticosteroid use, a

109 oid-related AEs increase systematically with corticosteroid dose.

110 We sought to analyze the role of MUC4 in corticosteroid effectiveness in different cohorts of pat

111 tential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obs

112 We hypothesized that MUC4 modulates corticosteroid efficacy of patients with CRSwNP.

113 that membrane-tethered mucins could mediate corticosteroid efficacy, interacting with glucocorticoid

114 the actions of corticosteroids and, in some, corticosteroids enhance their functional activation.

115 Eighty-one patients with CRSwNP took oral corticosteroids for 15 days.

116 To assess the effects of oral corticosteroids for acute lower respiratory tract infect

117 To assess the clinical effectiveness of oral corticosteroids for acute sore throat in the absence of

118 t of the children were treated with systemic corticosteroids for many months, yet all of them went on

119 key outcomes for this analysis were week 12 corticosteroid-free remission, defined as PUCAI less tha

120 ts diagnosed with severe AH and treated with corticosteroids from July 2006 through December 2013 in

121 eroid group, and 52 (36%) in the intravenous corticosteroid group (p<0.0001).

122 n the mesalazine group, 21 (15%) in the oral corticosteroid group, and 52 (36%) in the intravenous co

123 tients in the IFN group, in 1 patient in the corticosteroid group, and in 2 patients in the control g

124 nge in ACQ7 greater in the extrafine inhaled corticosteroids group than in the placebo group (differe

125 ma control, required higher doses of inhaled corticosteroids, had more severe airway hyperresponsiven

126 RATIONALE: Inhaled corticosteroids have been shown to decrease exacerbation

127 ith systemic chemotherapy therapies and oral corticosteroids; however, recurrences were common.

128 ], P = .001), and use of local injections of corticosteroids (HR = 2.37 [95% CI, 1.18-4.75], P = .02)

129 eneral expectation that early use of inhaled corticosteroid (ICS) could change the natural history of

130 sputum basophils following increased inhaled corticosteroid (ICS) treatment.

131 a comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) th

132 BACKGROUND AND Inhaled corticosteroids (ICS) and inhaled corticosteroids combin

133 ceiving either low- to medium-dosage inhaled corticosteroids (ICS) or low-dosage ICS plus long-acting

134 Inhaled corticosteroids (ICSs) are considered the most effective

135 assessment of the systemic effect of inhaled corticosteroids (ICSs) is often done by measuring 24-hou

136 efficacious as an add-on therapy to inhaled corticosteroids (ICSs) with or without other maintenance

137 d white subjects treated or not with inhaled corticosteroids (ICSs; ICS+ and ICS-, respectively).

138 veitis, and is currently being treated using corticosteroids, immunosuppressive agents, and biotherap

139 o long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease

140 sal corticosteroid rather than an intranasal corticosteroid in combination with an oral antihistamine

141 cells were used to investigate cytokine and corticosteroid in vitro regulation of CEACAM6 gene expre

142 We suggest not using corticosteroids in adult patients with sepsis without sh

143 corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-severe atopic

144 vidence-based recommendations for the use of corticosteroids in critically ill patients with sepsis a

145 ric oxide (FeNO) and the response to inhaled corticosteroids in patients with non-specific respirator

146 d withdrawal/avoidance to controls receiving corticosteroids in pediatric transplant recipients which

147 tively recorded in 398 patients treated with corticosteroids in the short term (from corticosteroid i

148 patients initially treated with intravenous corticosteroids included baseline total Mayo score of 11

149 fied in 6 studies that examined intravitreal corticosteroids, including triamcinolone (4) and the dex

150 ients with advanced CKD, the side effects of corticosteroids increase, and the renal protection decre

151 whether quinolone ear drops, with or without corticosteroids, increase the risk of perforation requir

152 e main symptomatic treatments are intranasal corticosteroids (INCS) (daily or on demand) and oral ant

153 eosinophils in sputum despite high doses of corticosteroids indicates disease severity in asthmatic

154 ant period, including conditioning regimens, corticosteroids, infections, and graft-versus-host disea

155 Among individuals with IBD, exposure to corticosteroids, infliximab or adalimumab, metronidazole

156 with corticosteroids in the short term (from corticosteroid initiation to 6 months) and long term (fr

157 it also identifies the therapeutic effect of corticosteroid initiation.

158 ver, neither QBA nor GSL showed an effect of corticosteroid initiation.

159 severe asthma and increased in patients with corticosteroid-insensitive severe asthma.

160 per cell type 2-mediated inflammation and/or corticosteroid insensitivity.

161 s and management of critical illness-related corticosteroid insufficiency (CIRCI) in adult and pediat

162 Anticoagulation, corticosteroids, intravenous immunoglobulin, and plasma

163 e asthma responds to treatment with systemic corticosteroids is not clear.

164 cerbation was defined as a burst of systemic corticosteroids lasting 3 days or more.

165 Early treatment with corticosteroids likely is beneficial.

166 Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted during w

167 Antenatal corticosteroids may be effective even if given only hour

168 Treatment with oral corticosteroids may help to reduce the risk of CNVM deve

169 A number of corticosteroid minimization and avoidance protocols for

170 s (PTDM) with 2 prolonged-release tacrolimus corticosteroid minimization regimens.

171 sion occurred in 11 (20%) patients receiving corticosteroid monotherapy and three (6%) patients on su

172 combinations are more effective than inhaled corticosteroid monotherapy in controlling disease exacer

173 In conclusion, only corticosteroid monotherapy induced disease remission in

174 Only corticosteroid monotherapy transiently reduced proteinur

175 l corticosteroids, suggesting a component of corticosteroid nonresponsive pathobiology in adults with

176 ion 1: ACP recommends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (N

177 hagitis (EoE) is limited to off-label use of corticosteroids not optimized for esophageal delivery.

178 n cohort (relatively high percentage on oral corticosteroids [OCS]).

179 The effect of oral corticosteroids on FEV1 , Pc20, airway inflammation and

180 ticipants in the LOCCS (Leukotriene Modifier Corticosteroid or Corticosteroid-Salmeterol) trial of th

181 ng proactive approaches (with either topical corticosteroids or topical calcineurin inhibitors) in mi

182 3 months requiring hospital attention, oral corticosteroids, or both.

183 ex, vitamin D dosing regimen, use of inhaled corticosteroids, or end-study 25(OH)D levels; post-hoc s

184 ed either subcutaneous IFN-alpha2a, systemic corticosteroids, or no treatment for 4 months.

185 66.9 (13.7) in those initiating intravenous corticosteroids (p<0.0001 for between-group comparison).

186 patients] who received placebo plus topical corticosteroids; p<0.0001) and EASI-75 (64% [204] and 69

187 Combination therapy with intranasal corticosteroid plus intranasal antihistamine is more eff

188 mains uncontrolled despite high-dose inhaled corticosteroids plus other controller medications.

189 ing despite regular use of high-dose inhaled corticosteroids plus other controller medicines.

190 nhaled fluticasone propionate (FP), systemic corticosteroids (Pred), or anti-IL-5.

191 ke breakthrough reaction rate of intravenous corticosteroid prophylaxis administered 5 hours before c

192 the cohort that received 5-hour intravenous corticosteroid prophylaxis.

193 orticosteroids (PUCAI 35-60), or intravenous corticosteroids (PUCAI >/=65).

194 treatment with mesalazine (PUCAI 10-30) oral corticosteroids (PUCAI 35-60), or intravenous corticoste

195 4 weeks of treatment with extrafine inhaled corticosteroids (QVAR 80 mug, two puffs twice per day, e

196 atients] who received dupilumab plus topical corticosteroids qw and 39% [41 patients] who received du

197 ely prescribe monotherapy with an intranasal corticosteroid rather than an intranasal corticosteroid

198 ne the association between preadmission oral corticosteroid receipt and the development of acute resp

199 roidal anti-inflammatory drugs (NSAIDs), and corticosteroids reduce pain in patients with acute gout.

200 en-induced eosinophilic lung inflammation to corticosteroid-refractory neutrophilic manifestation.

201 The incidence rates of corticosteroid-related AEs among placebo patients during

202 ase (P < 0.001 and P < 0.001) in the rate of corticosteroid-related AEs in VISUAL-1 and VISUAL-2, res

203 ISUAL-2 suggests that the incidence rates of corticosteroid-related AEs increase systematically with

204 nfidence interval (CI), 6.3-14.5; P < 0.001) corticosteroid-related AEs per year compared with a pati

205 additional 23.5 (95% CI, 7.6-52.7; P = 0.05) corticosteroid-related AEs per year compared with a pati

206 corticosteroid dosage and incidence rates of corticosteroid-related AEs.

207 each visit and included an assessment of the corticosteroid relationship by the investigator.

208 Colchicine, NSAIDs, and corticosteroids relieve pain in adults with acute gout.

209 MUC4beta participates in the corticosteroid resistance process, inhibiting normal GRa

210 Corticosteroid resistance was evaluated by using nasal e

211 oncept that severe asthma is associated with corticosteroid resistance.

212 atients with severe asthma appear relatively corticosteroid resistant.

213 ha in the nuclei of NP epithelial cells from corticosteroid-resistant patients.

214 f T-helper cell type 2 cytokines and lack of corticosteroid response (group 1 and group 3).

215 o identify key transcriptional regulators of corticosteroid response in asthma using a novel systems

216 tonide (TA), and to identify predictors of a corticosteroid response in these populations.

217 The primary outcome for corticosteroid response was defined as greater than or e

218 LTA4H genotype may predict adjunctive corticosteroid responsiveness in HIV-uninfected individu

219 Corticosteroid responsiveness is closely related to the

220 Corticosteroid responsiveness was common but not univers

221 Marked clinical and radiological corticosteroid responsiveness was observed in CLIPPERS (

222 of exacerbations, reduced lung function, and corticosteroid responsiveness.

223 f asthma exacerbations treated with systemic corticosteroids revealed that protective effects were se

224 Corticosteroids (RR, 0.18; 95% CI, 0.04-0.97; NNT, 12; 9

225 wice-daily long-acting beta2-agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500

226 OCCS (Leukotriene Modifier Corticosteroid or Corticosteroid-Salmeterol) trial of the American Lung As

227 lncRNA (PVT1) is decreased in patients with corticosteroid-sensitive nonsevere asthma and increased

228 Caffeine should be used routinely, while corticosteroids should be used judiciously, weighing up

229 Patients in arm 1 received tapered corticosteroids, stopped after day 10, whereas patients

230 Corticosteroids (such as betamethasone) and magnesium su

231 Modifiable risk factors, such as use of corticosteroids, suggest opportunities to reduce OHT ris

232 etween SA and NONSA persist after parenteral corticosteroids, suggesting a component of corticosteroi

233 gery predominantly in patients not receiving corticosteroids supports the prolonged use of corticoste

234 tic modalities, such as topical and systemic corticosteroids, systemic immunomodulators, topical and

235 Topical corticosteroid (TCS) phobia refers to the negative feeli

236 correlates with asthma that is refractory to corticosteroids, the mainstay of asthma treatment.

237 p avoid unnecessary morbidity from high-dose corticosteroid therapy and allow the most appropriate an

238 be a biomarker for responsiveness to inhaled corticosteroid therapy and may help identify patients as

239 ray of effector T cells that persist despite corticosteroid therapy and sustain chronic, smoldering v

240 Patients were also randomly assigned to corticosteroid therapy that included either dexamethason

241 Systemic corticosteroid therapy was not significantly associated

242 infusion (IVIG), with or without additional corticosteroid therapy, are common options, but optimal

243 After intensified local corticosteroid therapy, most patients show stable visual

244 dermatitis that was unresponsive to topical corticosteroid therapy.

245 ation at 90 and 180 days after initiation of corticosteroid therapy.

246 Nine patients received corticosteroid therapy.

247 due to DRESS is poor and was not improved by corticosteroid therapy.

248 Seven DMD boys were initiated on corticosteroids; these data were analyzed using a piecew

249 typically consists of intravenous fluids and corticosteroids (traditional therapy).

250 on demonstrated abrogation of differences in corticosteroid-treated cell viability following siRNA kn

251 patients treated with dupilumab plus topical corticosteroids-treated patients than in patients treate

252 y assigned 294 patients to extrafine inhaled corticosteroid treatment (n=148) or placebo (n=146).

253 umor development and treatment.Significance: Corticosteroid treatment during chemotherapy negatively

254 and post-hoc analyses of clinical trials of corticosteroid treatment for COPD have shown that the bl

255 Corticosteroid treatment inhibits IL-13-induced GCM of t

256 d conflicting messages about the benefits of corticosteroid treatment over supportive care alone, mos

257 After 8 days of topical corticosteroid treatment visual acuity was worsening wit

258 mmed cells Death-1 was stopped and a topical corticosteroid treatment was administrated.

259 hazard ratio [HR], 2.73), and previous oral corticosteroid treatment was associated with halving of

260 An oral corticosteroid treatment was started.

261 xacerbations requiring >/=3 days of systemic corticosteroid treatment were 0.066 and 0.147 with omali

262 Some groups were subjected to corticosteroid treatment with dexamethasone.

263 liver biopsies from 20 patients (9 received corticosteroid treatment), collected from January 2012 t

264 steroids and immunosuppression with regional corticosteroid treatment.

265 to aeroallergen sensitization, or to inhaled corticosteroid treatment.

266 ation among the RA patients according to the corticosteroid treatment; lowest in those taking the tre

267 Exacerbations requiring corticosteroids treatment were more common in the high v

268 ial radiation, regardless of MTX delivery or corticosteroid type.

269 whom were initially treated with intravenous corticosteroids, underwent colectomy.

270 9 years vs >/=9 years), duration of previous corticosteroid use (6 months to <12 months vs >/=12 mont

271 e suggests no benefit from bronchodilator or corticosteroid use in infants with a first episode of br

272 rior oral corticosteroid dose, prior topical corticosteroid use, and concomitant immunosuppressive dr

273 (n = 650), adjusting for smoking and inhaled corticosteroid use, and verified results in three other

274 After a run-in period to control for inhaled corticosteroid use, induced sputum was collected.

275 ry outcomes included BPD severity, postnatal corticosteroid use, respiratory support, survival, and n

276 exhaled nitric oxide levels, along with oral corticosteroid use, that could predict the subtypes of g

277 c oxide levels, exacerbation rates, and oral corticosteroid use, whereas group 3 patients showed the

278 measuring eosinophilic inflammation to guide corticosteroid use.

279 e symptoms once a week or more, and (5) oral corticosteroid use/emergency department visits.

280 ety of dupilumab with medium-potency topical corticosteroids versus placebo with topical corticostero

281 nts] who received dupilumab q2w plus topical corticosteroids vs 12% [39 patients] who received placeb

282 Higher doses of preadmission oral corticosteroids were associated with a lower incidence o

283 ening occurred in all 12 CLIPPERS cases when corticosteroids were discontinued.

284 Intravenous immunoglobulin and corticosteroids were effective in three patients, and on

285 ermatitis and inadequate response to topical corticosteroids were enrolled at 161 hospitals, clinics,

286 ICU patients with sepsis, preadmission oral corticosteroids were independently associated with a low

287 In multivariable analyses, preadmission oral corticosteroids were not associated with in-hospital mor

288 Treatments with systemic and topical corticosteroids were not significant risk factors.

289 the previous 2 years and no previous regular corticosteroids were randomised to receive once daily, i

290 ere exacerbations requiring oral or systemic corticosteroids were reduced (rate ratio 0.48 [0.38-0.61

291 Current clinical treatments use topical corticosteroids, which broadly and transiently suppress

292 Corticosteroids, which can cause severe adverse events,

293 recurrent nasal polyposis receiving topical corticosteroids who required surgery, mepolizumab treatm

294 doxycycline would be 25% less effective than corticosteroids with a 37% acceptable margin of non-infe

295 three groups were given concomitant topical corticosteroids with or without topical calcineurin inhi

296 Corticosteroid withdrawal/avoidance in pediatric renal t

297 study objective was to examine the effect of corticosteroid withdrawal/avoidance on growth and safety

298 ls (RCT) and observational studies comparing corticosteroid withdrawal/avoidance to controls receivin

299 Renal RCTs (n = 5) showed that corticosteroid withdrawal/avoidance was associated with

300 Corticosteroid withdrawal/avoidance was not associated w